New tool may predict kidney cancer drug success

NCT ID NCT02848768

Completed Knowledge-focused Sponsor: Rennes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a prediction tool (nomogram) to see if it could forecast how patients with metastatic clear cell renal cell carcinoma respond to the targeted therapy sunitinib. Researchers looked at 45 patients who had their kidney removed and were treated with sunitinib as their first therapy. The goal was to identify who would be resistant or respond well, potentially guiding better treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sunitinib
What this could lead to: If successful, this tool could help doctors predict which patients will benefit from sunitinib and which may need alternative treatments.
What could go wrong: This is a small, completed study that only validates a prediction model. It does not test a new treatment, and the tool may not be accurate for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma Clear-cell metastatic renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CLEAR CELL RENAL CELL CARCINOMA

Contacts and locations

Locations

CHU de Rennes

Rennes, 35033, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.